Risperidone
In brief
- In our pharmacy, you can buy risperidone without a prescription, with delivery in 9–21 days throughout the United Kingdom. Discreet and anonymous packaging.
- Risperidone is used for the treatment of schizophrenia, bipolar disorder (acute mania) and persistent aggression in conduct disorder or Alzheimer’s dementia (short-term); it is an atypical antipsychotic that antagonises dopamine D2 and serotonin 5‑HT2A receptors.
- The usual dose of risperidone is 2–6 mg daily (typical starting dose 1–2 mg daily, maintenance 4–6 mg; usual therapeutic range 1–8 mg/day), titrated to response and tolerability.
- The form of administration is oral tablets, orally disintegrating tablets, oral solution and intramuscular long‑acting injectable (depot) formulations.
- Some effects such as sedation may begin within 30–60 minutes; antipsychotic benefits often start over days with clearer improvement after 1–2 weeks and full effect over several weeks.
- The duration of action is about 24 hours for oral dosing; the long‑acting injectable formulation provides therapeutic coverage for approximately two weeks per dose.
- Do not consume alcohol or use only with caution and medical advice — alcohol increases drowsiness, dizziness and the risk of falls and other adverse effects.
- The most common side effect is drowsiness (sedation).
- Would you like to try risperidone without a prescription?
Basic risperidone information
- INN (international nonproprietary name): Risperidone
- Brand names available in the United Kingdom: Risperdal; Risperdal Consta; generic risperidone
- ATC code: N05AX08
- Forms and dosages: tablets (0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg, 6 mg), orodispersible tablets, oral solution 1 mg/ml and long-acting injection (25 mg, 37.5 mg, 50 mg)
- Manufacturers in the United Kingdom: Janssen-Cilag (Risperdal) and generic manufacturers
- Registration status in the United Kingdom: Prescription-only medicine (POM)
- OTC / Rx classification: Prescription only (Rx)
Critical warnings and restrictions
High-risk groups
Starting risperidone raises immediate safety questions patients and prescribers often ask first.
Never start, stop or change risperidone dosing without approval from the prescriber who manages your care.
Seek urgent medical review if a patient develops marked restlessness or akathisia, severe sedation, signs of neuroleptic malignant syndrome (high fever, muscle rigidity, autonomic instability) or new or worsening suicidal thoughts.
Elderly patients with dementia-related psychosis are at increased risk of cerebrovascular events and mortality when treated with antipsychotics.
Pregnant or breastfeeding women should have a careful risk–benefit discussion with their prescriber and receive contraception counselling as appropriate.
People with severe hepatic or renal impairment may need dose adjustments or an alternative treatment and require closer monitoring.
Children and adolescents need age-appropriate licensed indications and closer monitoring of growth, weight and metabolic parameters while on risperidone.
People with Parkinson’s disease or Lewy body dementia may be especially sensitive to antipsychotics and can deteriorate; specialist input is required.
Use this pre-prescription safety checklist before initiating risperidone in primary or secondary care.
- Allergies and prior antipsychotic reactions.
- Cardiac history, especially arrhythmia, syncope or prolonged QT on prior ECG.
- Current medicines with QT risk, CYP2D6 inhibitors or CNS depressants.
- Baseline weight, height and BMI measurement.
- Baseline bloods: fasting glucose or HbA1c, lipids, liver and renal function, and, if indicated, prolactin.
Interaction with activities
Patients must be warned about drowsiness, dizziness, blurred vision and orthostatic hypotension that can occur when starting or increasing risperidone.
Under UK law the Driver and Vehicle Licensing Agency (DVLA) requires disclosure of medication if sedative effects impair safe driving.
Employers should be informed if medication affects the ability to perform safety-critical tasks, subject to workplace policies and confidentiality considerations.
Q&A — “Can I drive after taking it in the UK?”
Short answer: Not if you feel sleepy, dizzy or your coordination is impaired.
Legally you must not drive if medication affects safe driving and you should follow clinician advice about informing the DVLA when advised.
If in doubt, avoid driving and check with your prescriber or pharmacist before resuming driving duties.
Usage basics
INN, brand names available in the UK
The International Nonproprietary Name (INN) is risperidone.
In the United Kingdom risperidone is commonly available as Risperdal, Risperdal Consta prolonged-release injection, generic risperidone tablets, oral solution and other depot injections where marketed.
Formulations for risperidone vary in strengths such as 0.5 mg, 1 mg, 2 mg, 3 mg and 4 mg tablets, and multiple injection preparations for depot use.
Below is a quick reference table mapping common formulations to typical strengths and brands as used in UK practice.
| Formulation | Typical strengths | Common UK brands |
|---|---|---|
| Tablets | 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg | Generic risperidone; Risperdal |
| Oral solution | 1 mg/ml | Generic risperidone oral solution |
| Prolonged-release injection (depot) | Risperdal Consta IM every 2 weeks; other depot formats vary | Risperdal Consta |
Legal classification
Risperidone is a Prescription Only Medicine (POM) in the United Kingdom and may only be supplied on an NHS or private prescription by a pharmacist under clinician direction.
Electronic Prescription Service (EPS) and hospital discharge prescriptions are common lawful supply routes.
Pharmacists must provide counselling at the point of supply and remote consultations must still ensure safe prescribing and verification of identity.
- POM = Prescription Only Medicine.
- EPS = Electronic Prescription Service.
- MHRA = Medicines and Healthcare products Regulatory Agency.
Dosing guide
Standard regimens
Prescribers generally start risperidone at a low dose and titrate to clinical effect while watching for side effects.
Typical starting oral doses are 0.5–1 mg twice daily or 1 mg once daily depending on the presentation and formulation used.
Maintenance doses commonly range from 2–6 mg per day and are personalised to the patient’s response and tolerability.
Maximum doses are often limited to 8 mg per day in routine practice, though local guidance and specialist advice may vary.
For schizophrenia, bipolar mania and aggression in neurodevelopmental conditions dosing regimens differ and need to be diagnosis-specific.
Risperdal Consta prolonged-release injection is typically administered intramuscularly every two weeks with oral cover during initiation.
Stepwise titration examples and monitoring schedule are listed below.
- Schizophrenia (adult): start 1–2 mg/day, increase by 1 mg every 1–2 days based on response to a common maintenance 4 mg/day.
- Bipolar mania (acute control): start 2 mg/day and adjust depending on response and sedation.
- Persistent aggression in conduct disorder (children/adolescents): lower starting doses with careful weight and metabolic monitoring.
- Prolonged-release injection: give IM every 2 weeks; provide oral risperidone for 3 weeks after first injection if using Risperdal Consta.
- Monitoring schedule: baseline ECG (if cardiac risk), weight/BMI, fasting glucose or HbA1c, lipids, liver and renal function, and EPS/prolactin monitoring if symptomatic.
Adjustments for comorbidities
Dose reductions or slower titration are recommended for patients with renal or hepatic impairment, and for frail elderly patients.
CYP2D6 inhibitors such as strong SSRI inhibitors can increase risperidone exposure and may require dose change or extra vigilance.
For depot injections coordinate administration and possible oral overlap with the prescriber and local mental health team to avoid gaps in therapy.
Q&A — “What if I miss a dose?”
If an oral dose is missed, take it as soon as you remember on the same day.
Do not double up within 12 hours to make up a missed dose.
Resume the usual schedule the next day and contact NHS 111 or your pharmacist if you are unsure.
If a depot injection is missed, contact your prescriber immediately because timing affects whether oral cover or catch-up injections are required.
Interaction chart
Food and drinks
Alcohol potentiates sedation and orthostatic hypotension and should be avoided or minimised when starting or increasing risperidone.
Caffeine may mask sedation but can increase anxiety or tremor in some patients.
No major dietary restrictions are required, but lifestyle support is important because weight gain and metabolic change are common.
Common drug conflicts
Key pharmacokinetic and pharmacodynamic interactions include CYP2D6 inhibitors, QT-prolonging medicines and CNS depressants.
| Drug | Interaction type | Clinical action |
|---|---|---|
| Fluoxetine, paroxetine | CYP2D6 inhibition → increased risperidone levels | Monitor; consider dose reduction or alternative where appropriate |
| Other QT-prolonging drugs (e.g. some antiarrhythmics) | Increased arrhythmia risk | Avoid combination if possible; ECG monitoring if necessary |
| Benzodiazepines, opioids | Pharmacodynamic sedation and respiratory depression | Use lowest effective doses; monitor closely |
| Dopamine agonists (e.g. levodopa) | Pharmacodynamic antagonism → reduced efficacy | Coordinate specialist care for Parkinson’s disease patients |
Pharmacists should review concomitant medicines at each supply and use a short checklist for interactions and monitoring.
- Review current medicines for CYP interactions.
- Check for QT risk and advise ECG where indicated.
- Assess CNS depressant load and counsel on sedation.
Legal status and availability in the UK
In our online pharmacy, risperidone is available without a prescription, with discreet delivery to the United Kingdom in 9–21 days.
Mechanism and pharmacology
Simplified explanation
Risperidone is an atypical antipsychotic that primarily antagonises dopamine D2 receptors and serotonin 5-HT2A receptors.
This dual action reduces positive psychotic symptoms such as hallucinations and delusions and can improve mood and behavioural disturbances.
At clinical doses risperidone also affects adrenergic, histaminergic and muscarinic receptors, which contribute to sedation, weight gain and orthostatic hypotension.
Clinical terms
- D2 antagonism → antipsychotic efficacy.
- 5-HT2A antagonism → reduced risk of extrapyramidal symptoms and potential mood benefits.
- Alpha-1 blockade → orthostatic hypotension risk.
- H1 blockade → sedation and appetite increase leading to weight gain.
Indications and off-label uses
MHRA-approved uses
Licensed indications for risperidone commonly include schizophrenia and schizoaffective disorder in adults.
Risperidone is also licensed for moderate-to-severe manic episodes associated with bipolar disorder, for short-term treatment of persistent aggression in moderate to severe Alzheimer’s dementia, and for short-term treatment of persistent aggression in conduct disorder in children from 5 years and adolescents with intellectual disability.
Depot formulations are licensed for maintenance therapy in schizophrenia and schizoaffective disorder.
Off-label practices in NHS and private care
Use for behavioural disturbance in dementia beyond the licensed short-term indication is off-label, and antipsychotics are generally avoided in dementia because of increased mortality risk.
Other off-label scenarios include aggression in intellectual disability when psychosocial measures fail and specialist augmentation in refractory depression.
| Indication | Licensed vs off-label | Usual approach |
|---|---|---|
| Schizophrenia | Licensed | Standard antipsychotic therapy per NICE |
| Dementia-related behaviour | Licensed only for short-term persistent aggression in Alzheimer’s dementia; otherwise off-label; caution | Non-pharmacological first; document rationale and monitoring if used |
| Aggression in conduct disorder | Licensed from 5 years (with intellectual disability) | Follow product licence for age and monitor growth and metabolic effects |
For off-label prescribing ensure documented rationale, informed consent and a clear monitoring and review plan.
Alternatives matrix
NHS prescribing alternatives
| Drug | Efficacy for psychosis | Sedation risk | Metabolic risk | EPS risk | Depot options |
|---|---|---|---|---|---|
| Olanzapine | High | High | High | Low–Moderate | Yes (IM available) |
| Quetiapine | Moderate | Moderate | Moderate | Low | Limited |
| Aripiprazole | Moderate | Low | Low | Low | Yes (long-acting) |
| Haloperidol | High | Low | Low | High | Yes (short-acting depot) |
| Amisulpride | Moderate | Low | Low | Moderate | Limited |
Pros and cons checklist
- Assess symptom profile: positive versus negative symptoms and agitation.
- Review metabolic history including diabetes or dyslipidaemia.
- Check cardiac/QT history and current medicines.
- Decide if sedation is desirable for acute agitation or undesirable for day-to-day functioning.
- Discuss oral versus depot preference and adherence concerns with the patient.
- Document shared decision-making, rationale and monitoring plan.
Common questions
Patients frequently ask a small number of practical questions about risperidone.
Will risperidone make me gain weight?
Many people gain weight because risperidone can increase appetite and cause metabolic changes.
Baseline and periodic weight, BMI and metabolic blood tests are standard practice to detect and manage changes early.
Discuss diet and activity support and consider switching to an alternative antipsychotic if weight gain is unacceptable.
How quickly will it work?
Some symptoms such as agitation and insomnia may improve within days of starting treatment.
The full antipsychotic benefit often takes several weeks and close early follow-up is important for side-effect monitoring and suicidality assessment.
What monitoring is needed?
Baseline and periodic checks usually include weight, BMI, blood pressure, fasting glucose or HbA1c and lipids.
ECG and prolactin measurement are indicated if cardiac history or prolactin-related symptoms occur.
For depot injections monitor the injection site and adherence records.
Can I stop it when I feel better?
Do not stop risperidone abruptly without medical advice because sudden withdrawal can increase relapse risk.
A gradual taper supervised by the prescriber is the safest route and should include a follow-up and crisis plan.
Registration and regulation
MHRA approval process
Medicines used in the UK are authorised by the MHRA following marketing authorisation, safety monitoring and periodic reviews.
Pharmacovigilance runs through the Yellow Card Scheme for reporting suspected adverse drug reactions.
- MHRA = Medicines and Healthcare products Regulatory Agency.
- Yellow Card = UK adverse drug reaction reporting scheme.
NHS prescribing framework
Shared-care arrangements are common when risperidone is initiated by a specialist and continued by a GP, with clear documentation of responsibilities.
NICE guidance and local formularies influence first-line choices and preferred depot options across NHS trusts.
Prescribers should confirm the licence for the indication and age group, obtain informed consent, and document a monitoring plan in the patient record.
Storage and handling
UK household storage (cold/damp climate)
Tablets and oral solution should be stored at room temperature away from heat and moisture in the original container.
Depot and IM products should follow manufacturer guidance; some require refrigeration at 2–8°C before administration and should not be frozen.
In UK homes avoid storing medicines in bathrooms or near windows where condensation and temperature changes occur.
Guidance from NHS and pharmacists
- Return unwanted or expired medicines to your pharmacy for safe disposal.
- Injection administration is usually clinic-based; if self-administration is ever arranged, follow training and local sharps disposal advice.
- When transporting medicines keep them in original packaging and use a cold pack for refrigerated products when supplied for home use.
Pharmacists should confirm storage at point of dispense and provide written leaflets and emergency contact details for missed injections.
Guidelines for proper use
UK pharmacist counselling style
Pharmacist counselling should address the indication, expected benefits and common and serious side effects in clear, plain language.
Discuss interactions with alcohol and other medicines, driving and workplace implications and how to take tablets or manage injection appointments.
Use teach-back to confirm patient understanding and provide a printed or electronic copy of monitoring schedules and crisis contacts.
NHS patient safety advice
Carry a current medication list and crisis contact numbers and never share prescription medicine with others.
Report adverse effects via the Yellow Card Scheme or to the prescriber and attend monitoring appointments for weight, BP and blood tests.
For depot therapy attend appointments on schedule and inform the team promptly about missed injections.
- Keep a documented care plan with review dates and clearly set monitoring responsibilities.
- If switching formulations arrange a stepwise plan and follow local shared-care agreements.
Delivery across the United Kingdom
| City | Region | Delivery Time |
|---|---|---|
| London | England | 9–21 days |
| Birmingham | England | 9–21 days |
| Manchester | England | 9–21 days |
| Glasgow | Scotland | 9–21 days |
| Leeds | England | 9–21 days |
| Liverpool | England | 9–21 days |
| Edinburgh | Scotland | 9–21 days |
| Bristol | England | 9–21 days |
| Sheffield | England | 9–21 days |
| Newcastle | England | 9–21 days |
| Nottingham | England | 9–21 days |
| Southampton | England | 9–21 days |
| Belfast | Northern Ireland | 9–21 days |